Health
Immune dysregulation can affect the efficacy of CAR T therapy in some lymphoma patients – News-Medical.Net
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large…
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Clinical studies have shown overall response rates of more than 80% with an ongoing response of nearly 40% more than two years after therapy. However, the cellular immunotherapy doesn’t work for every patient.
Moffitt Cancer Center, one of the leading centers for cellular immunotherapy, is researching why some patients…
-
General24 hours agoUK names Sarah Mullally as first female Archbishop of Canterbury to lead Church of England
-
General24 hours agoSussan Ley responds to Andrew Hastie’s Shadow Cabinet resignation
-
General22 hours agoa pivotal moment in Liberal power struggle
-
Noosa News22 hours agoTayla Harris stars as Melbourne defeats Essendon by 14 points